|

VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

RECRUITINGPhase 2Sponsored by Inova Health Care Services
Actively Recruiting
PhasePhase 2
SponsorInova Health Care Services
Started2026-09-04
Est. completion2027-09-30
Eligibility
Age18 Years – 98 Years
Healthy vol.Accepted
Locations1 site

Summary

The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas

Eligibility

Age: 18 Years – 98 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosis of glioblastoma or IDH-mutated glioma by WHO 2021 classification
* For glioblastoma, at least one prior treatment, which needs to include temozolomide and/or radiation
* For IDH-mutated glioma, prior treatment with both radiation and alkylating chemotherapy
* Evidence of progression by RANO 2.0 criteria on MRI within last four weeks
* At least 1 enhancing measurable lesion

Exclusion Criteria:

* Use of an enzyme-inducing antiepileptic or other strong inducer of CYP3A4
* Prior treatment with irinotecan
* Prior use of valproic acid within 2 months
* Anticancer treatment within 4 weeks, 6 weeks if nitrosourea
* Active bacterial or fungal infection requiring systemic treatment
* Pregnancy
* Known mitochondrial disease

Conditions3

Astrocytoma, IDH-Mutant, Grade 4CancerGlioblastoma

Interventions3

Locations1 site

Inova Schar Cancer
Fairfax, Virginia, 22031
Keary Jane't571-472-3173keary.jane't@inova.org

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.